Theravance Biopharma TBPH Other income, net (Note 6)
Other income, net (Note 6) at other companies
Segments
By segment
Other financials
Where this comes from
Reported directly by Theravance Biopharma in its filing.
Tagged under the XBRL concept us-gaap:OtherNonoperatingIncomeExpense.
The official record: Theravance Biopharma’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Theravance Biopharma's other income, net (note 6).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Theravance Biopharma's other income, net (note 6)?
- Theravance Biopharma (TBPH) reported other income, net (note 6) of $3.01M in Q1 2026.
- How has Theravance Biopharma's other income, net (note 6) changed year-over-year?
- Theravance Biopharma's other income, net (note 6) increased by 220.9% year-over-year, from $939K to $3.01M.
- What is the long-term trend for Theravance Biopharma's other income, net (note 6)?
- Over 4 years (2021 to 2025), Theravance Biopharma's other income, net (note 6) has grown at a 74.0% compound annual growth rate (CAGR), from $1.11M to $10.17M.
- What does other income, net (note 6) mean?
- This captures miscellaneous financial items that fall outside the scope of core operating activities, such as foreign exchange gains or losses, minor investment income, or non-recurring legal settlements. It serves as a catch-all for peripheral financial events that do not stem from the primary business operations. Investors monitor this to isolate core earnings from transient or incidental financial fluctuations.